ArticleMolecules (Basel, Switzerland)2026
Wound Healing Potential of the Salvianolic Acid H and Yunnaneic Acid B-The Rosmarinic Acid Derivatives: Anti-Inflammatory Action and Hemocompatibility In Vitro.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Phenolic acids of plant origin are recognized as key bioactive compounds with potential for both internal and topical applications. Although some of these phytochemicals are used for skin care and to improve wound healing, oligomeric derivatives of rosmarinic acid (RA) remain poorly characterized in this context. This study aimed to evaluate the anti-inflammatory potential of salvianolic acid H (SA H) and yunnaneic acid B (YA B) in experimental models related to wound-healing, specifically in skin cells (HaCaT keratinocyte and NHDF fibroblast lines), THP1-ASC-GFP monocytes, and human peripheral blood mononuclear cells (PBMCs). Both SA H and YA B reduced pro-inflammatory cytokine release from HaCaT, NHDF, and PBMCs with efficacy comparable to or exceeding that of RA. Analyses of intracellular pathways of inflammatory response revealed that SA H and YA B were also efficient inhibitors of inflammasome formation in THP1-ASC-GFP reporter cells. Furthermore, SA H showed significant inhibitory effects on the activities of cyclooxygenase-2 and 5-lipoxygenase (IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.